Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Pediatr Blood Cancer ; 71(8): e31078, 2024 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-38794793

RESUMO

Infantile pyknocytosis (IP) is a rare, probably misestimated, cause of non-immune neonatal hemolytic anemia evolving in two phases: an initial phase with severe jaundice, followed by a second phase with hemolytic anemia, which may require neonatal intensive care. The diagnosis of IP is based on the transient presence on blood smear of hyperdense, contracted, and/or spiculated red blood cells (pyknocytes), associated with the spontaneous resolution of clinico-biological features and the exclusion of other causes. If the etiology remains undetermined, some contributing factors, such as oxidative stress, have been proposed. We report the description of 16 patients with IP aiming at clarifying the circumstances associated with the development of this acquired disorder. In the acute phase, the mean hemoglobin nadir and pyknocyte count were 7.8 g/dL and 11%, respectively, and strikingly, Heinz bodies were evident in 50% of the newborns, but in 100% after prolonged incubation (4 hours). A high proportion of Mediterranean or African ancestry was noted in newborns, as well as a significant number of peripartum events, such as respiratory distress. If the etiology of IP is certainly multifactorial, our series reinforces the role of oxidative stress, which may, at least in part, find origin in desaturation episodes in newborns.


Assuntos
Corpos de Heinz , Humanos , Recém-Nascido , Feminino , Masculino , Estudos de Coortes , Anemia Hemolítica/patologia , Anemia Hemolítica/sangue , Lactente , Anemia Neonatal/sangue , Anemia Neonatal/patologia
3.
J Thromb Haemost ; 19(8): 1959-1972, 2021 08.
Artigo em Inglês | MEDLINE | ID: mdl-33872452

RESUMO

BACKGROUND: Diagnosis of heparin-induced thrombocytopenia (HIT) requires pretest probability assessment and dedicated laboratory assays. OBJECTIVE: To develop a pretest score for HIT. DESIGN: Observational; analysis of prospectively collected data of hospitalized patients suspected with HIT (ClinicalTrials.gov NCT00748839). SETTING: Thirty-one tertiary hospitals in France, Switzerland, and Belgium. PATIENTS: Patients tested for HIT antibodies (2280 evaluable), randomly allocated to derivation and validation cohorts. MEASUREMENTS: Independent adjudicators diagnosed HIT based on the prospectively collected data and serotonin release assay results. RESULTS: Heparin-induced thrombocytopenia was diagnosed in 234 (14.7%) and 99 (14.5%) patients in the two cohorts. Eight features were associated with HIT (in brackets, points assigned for score calculation of the score): unfractionated heparin (1); therapeutic-dose heparin (1); cardiopulmonary bypass (cardiac surgery) (2); major trauma (3); 5- to 21-day interval from anticoagulation initiation to suspicion of HIT (4); ≥40% decrease in platelet count over ≤6 days (3); thrombotic event, arterial (3) or venous (3). The C-statistic was 0.79 (95% CI, 0.76-0.82). In the validation cohort, the area under the receiver operating characteristic curve was 0.77 (95% CI, 0.74-0.80). Three groups of scores were defined; HIT prevalence reached almost 30% in the high-probability group. LIMITATION: The performance of the score may depend on settings and practices. CONCLUSION: The objective, easy-to-collect, clinical features of HIT we evidenced were incorporated into a pretest score, which may guide clinical decisions regarding diagnostic testing and anticoagulation.


Assuntos
Heparina , Trombocitopenia , Anticoagulantes/efeitos adversos , Heparina/efeitos adversos , Humanos , Contagem de Plaquetas , Estudos Prospectivos , Trombocitopenia/induzido quimicamente , Trombocitopenia/diagnóstico , Trombocitopenia/epidemiologia
4.
Thromb Haemost ; 120(7): 1096-1107, 2020 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-32572863

RESUMO

BACKGROUND: Heparin-induced thrombocytopenia (HIT) is a rare complication of heparin treatments, and only a few large patient cohorts have been reported. In this study, biological and clinical data from 144 French patients with HIT were analyzed in comparison with the literature. METHODS: The diagnosis of HIT was confirmed in all patients by an immunoassay combined with serotonin release assay. In the literature, only cohorts of at least 20 HIT patients published from 1992 were selected for a comparative analysis. RESULTS: Two-thirds of patients were hospitalized in surgery and most were treated with unfractionated heparin (83.2% vs. 16.8% with low molecular weight heparin only). Thrombotic events in 54 patients (39.7%) were mainly venous (41/54). However, arterial thrombosis was more frequent after cardiac surgery (13.2% vs. 2.4% in other surgeries, p = 0.042) with a shorter recovery time (median = 3 vs. 5 days, p < 0.001). The mortality rate was lower in our series than in the 22 selected published studies (median = 6.3% vs. 15.9%). Three genetic polymorphisms were also studied and homozygous subjects FcγRIIA RR were more frequent in patients with thrombosis (37.8 vs. 18.2% in those without thrombosis, p = 0.03). CONCLUSION: This study shows that the mortality rate due to HIT has recently decreased in France, possibly due to earlier diagnosis and improved medical care. It also confirms the strong association between polymorphism FcγRIIA H131R and thrombosis in HIT.


Assuntos
Anticoagulantes/efeitos adversos , Heparina/efeitos adversos , Trombocitopenia/induzido quimicamente , Adulto , Idoso , Idoso de 80 Anos ou mais , Antígenos de Plaquetas Humanas/genética , Feminino , França , Humanos , Integrina beta3/genética , Masculino , Pessoa de Meia-Idade , Molécula-1 de Adesão Celular Endotelial a Plaquetas/genética , Polimorfismo Genético , Prognóstico , Estudos Prospectivos , Receptores de IgG/genética , Medição de Risco , Fatores de Risco , Trombocitopenia/diagnóstico , Trombocitopenia/mortalidade , Trombocitopenia/terapia , Fatores de Tempo , Adulto Jovem
6.
Ann Biol Clin (Paris) ; 74(6): 704-707, 2016 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-27734802

RESUMO

We report a 60-year-old adult case with a normocytic normochromic regenerative anemia discovered incidentally. The objectification of elliptocytosis accompanied by splenomegaly, a collagen myelofibrosis and the presence of the mutation JAK2V617F allowed the diagnosis of primary myelofibrosis with atypical initial presentation. The causes of elliptocytoses are discussed.


Assuntos
Anemia/diagnóstico , Eliptocitose Hereditária/diagnóstico , Anemia/complicações , Anemia/genética , Eliptocitose Hereditária/complicações , Eliptocitose Hereditária/genética , Humanos , Achados Incidentais , Janus Quinase 2/genética , Masculino , Pessoa de Meia-Idade , Mutação , Mielofibrose Primária/complicações , Mielofibrose Primária/diagnóstico , Mielofibrose Primária/genética
8.
World J Gastroenterol ; 19(5): 773-5, 2013 Feb 07.
Artigo em Inglês | MEDLINE | ID: mdl-23431107

RESUMO

Increased ischemic stroke risk is observed in patients with inflammatory bowel disease (IBD). Causes and physiopathological aspects of cerebral infarct, in this specific population, are less often described. There is little information to provide guidelines for the best curative and preventive treatment. We report 2 cases of ischemic strokes due to internal carotid thrombus in patients during active phase of IBD. Ulceration of early atherosclerotic plaques activated by a hypercoagulation state may cause a thrombus. A combined therapy with heparin and corticosteroids was used for both our patients. Lysis of the thrombus was obtained after several days without surgical treatment and shown by ultrasonography. These cases highlight an aetiology of stroke in patients with IBD and use of a synergic treatment to respond to hypercoagulability in link with IBD. Benefits and safety of this therapy should be confirmed with clinical studies.


Assuntos
Doenças das Artérias Carótidas/etiologia , Trombose das Artérias Carótidas/etiologia , Artéria Carótida Interna , Colite Ulcerativa/complicações , Doença de Crohn/complicações , Corticosteroides/uso terapêutico , Adulto , Anticoagulantes/uso terapêutico , Coagulação Sanguínea , Isquemia Encefálica/etiologia , Doenças das Artérias Carótidas/sangue , Doenças das Artérias Carótidas/diagnóstico , Doenças das Artérias Carótidas/tratamento farmacológico , Trombose das Artérias Carótidas/sangue , Trombose das Artérias Carótidas/diagnóstico , Trombose das Artérias Carótidas/tratamento farmacológico , Artéria Carótida Interna/diagnóstico por imagem , Artéria Carótida Interna/metabolismo , Colite Ulcerativa/sangue , Colite Ulcerativa/diagnóstico , Colite Ulcerativa/tratamento farmacológico , Doença de Crohn/sangue , Doença de Crohn/diagnóstico , Doença de Crohn/tratamento farmacológico , Feminino , Heparina/uso terapêutico , Humanos , Masculino , Acidente Vascular Cerebral/etiologia , Terapia Trombolítica , Fatores de Tempo , Resultado do Tratamento , Ultrassonografia
9.
Blood Cells Mol Dis ; 46(3): 235-8, 2011 Mar 15.
Artigo em Inglês | MEDLINE | ID: mdl-21306925

RESUMO

Essential thrombocythemia and polycythemia vera are myeloproliferative disorders (MPD) with an elevated thrombotic risk. Leukocytosis has recently emerged as a new risk factor and there is increasing evidence that polymorphonuclear neutrophils (PMN) are involved. Procoagulant activity (PCA) of PMN in MPD has not yet been investigated. PCA of PMN from 22 patients with JAK2(V617F) positive MPD and 26 healthy subjects was studied using calibrated automated thrombography: in vitro thrombin generation induced with 1 pM tissue factor in the presence of added procoagulant phospholipids. There were no differences between patients and controls regarding the ability of PMN to increase thrombin generation. More surprisingly, basal thrombin generation in acellular MPD-plasma was found decreased for as yet unknown reasons. The presence of an active protein C pathway or platelets might provide a better insight into the coagulation phenotype in MPD.


Assuntos
Testes de Coagulação Sanguínea , Janus Quinase 2/metabolismo , Transtornos Mieloproliferativos/fisiopatologia , Neutrófilos/patologia , Trombofilia/metabolismo , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Neutrófilos/metabolismo , Policitemia Vera/metabolismo , Policitemia Vera/fisiopatologia , Trombina/metabolismo , Trombocitemia Essencial/metabolismo , Trombocitemia Essencial/fisiopatologia
10.
Platelets ; 22(2): 157-9, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21142409

RESUMO

This case describes the medical history of a 61-year-old woman treated for cerebral venous thrombosis (CVT) leading to diagnosis of essential thrombocythemia (ET). During treatment with unfractionated heparin, after initial improvement of clinical state, signs of cerebral hypertension reappeared. Although the platelet count decreased, heparin-induced thrombocytopenia (HIT) was only suspected 2 days later when it dropped below the standard 150 × 10(9) L(-1) threshold. HIT diagnosis was confirmed by the presence of anti-PF4/heparin IgG. This late finding was the cause of the extension of CVT with worsening of cerebral hypertension necessitating decompressive craniectomy. Elevated basal platelet count due to ET can delay diagnosis and treatment of HIT. In this case, physicians should be more attentive to platelet count variations rather than thrombocytopenia threshold.


Assuntos
Anticoagulantes/efeitos adversos , Veias Cerebrais/patologia , Heparina/efeitos adversos , Trombocitemia Essencial/complicações , Trombocitopenia , Trombose/induzido quimicamente , Trombose Venosa/etiologia , Anticoagulantes/uso terapêutico , Veias Cerebrais/diagnóstico por imagem , Veias Cerebrais/cirurgia , Sulfatos de Condroitina/uso terapêutico , Craniectomia Descompressiva , Dermatan Sulfato/uso terapêutico , Feminino , Heparina/uso terapêutico , Heparitina Sulfato/uso terapêutico , Humanos , Hipertensão Intracraniana/diagnóstico por imagem , Hipertensão Intracraniana/etiologia , Hipertensão Intracraniana/cirurgia , Pessoa de Meia-Idade , Contagem de Plaquetas , Radiografia , Trombocitemia Essencial/tratamento farmacológico , Trombocitopenia/induzido quimicamente , Trombocitopenia/complicações , Trombose/complicações , Resultado do Tratamento , Trombose Venosa/diagnóstico por imagem , Trombose Venosa/tratamento farmacológico , Trombose Venosa/cirurgia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA